Novel Clinical Applications of Topical Ruxolitinib: A Case Series
J Drugs Dermatol. 2024 Mar 1;23(3):188-190. doi: 10.36849/jdd.7696.ABSTRACTTopical ruxolitinib, a potent Janus kinase (JAK) inhibitor, has shown significant efficacy in treating inflammatory skin conditions. While its use has already been established in atopic dermatitis and vitiligo, recent reports suggest its potential efficacy in treating other dermatoses. Specifically, topical ruxolitinib may be an effective treatment option for refractory dermatological conditions that are inflammation-driven with dysregulated activity of cytokines implicated in the JAK/STAT pathway. In this case series, we present four novel clinical...
Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Melissa P Zundell Roudha Al-Dehneem Teresa Song Jenna Yousif Alice B Gottlieb Source Type: research
